Drug Trial Radar · NCT06594211
Allogeneic Anti-BCMA/GPRC5D Bispecific CAR-NK Cells (ACT-001) in Patients With Relapsed or Refractorymultiple Myeloma
Last checked: Nov 19, 2026Latest source record: Sep 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
18
Planned (sponsor's estimate)
Start
Oct 9, 2024
Primary completion
Oct 9, 2028
Study completion Oct 9, 2028
Sponsor
- Lead sponsor
- RenJi HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Acellytron Therapeutics
- First posted
- Sep 19, 2024
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a single-arm, open-label, exploratory clinical study to evaluate the safety and efficacy of allogeneic anti-BCMA/GPRC5D bispecific chimeric antigen receptor natural killer (CAR-NK) cells (ACT-001) in patients with refractory or relapsed multiple myeloma (r/r MM).
Conditions
- Multiple Myeloma
Interventions
ACT-001 CAR-NK cellBiological
Subjects were distributed into three dosage groups, each receiving a single dose of CAR-NK cells at levels of 1×10\^8, 3×10\^8, and 9×10\^8 cells, respectively.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose-limiting toxicity (DLT)Time frame: From admission to 28 days after CAR-NK cells infusion
- Incidence and type of adverse events (AEs)Time frame: From admission to 2 years after CAR-NK cells infusion
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Renji Hospital, Shanghai Jiaotong University School of Medicine
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.